Identification

Name
Metamizole
Accession Number
DB04817
Type
Small Molecule
Groups
Approved, Investigational, Withdrawn
Description

Metamizole, formerly marketed as Dimethone tablets and injection, Protemp oral liquid, and other drug products, was associated with potentially fatal agranulocytosis. Approvals of the NDA's for dipyrone drug products were withdrawn on June 27, 1977 (see the Federal Register of June 17, 1977 (42 FR 30893)). Withdrawn from the Canadian market in 1963.

Structure
Thumb
Synonyms
Not Available
Product Ingredients
IngredientUNIICASInChI Key
Metamizole magnesiumMS156427256150-97-6Not applicable
Metamizole sodiumNot Available68-89-3DJGAAPFSPWAYTJ-UHFFFAOYSA-M
Metamizole sodium monohydrate6429L0L52Y5907-38-0Not applicable
International/Other Brands
Algocalmin / Algozone / Analgin / Dimethone / Dipirona / Neo-Melubrina / Novalgin / Optalgin / Protemp / Pyralgin
Categories
UNII
VSU62Z74ON
CAS number
50567-35-6
Weight
Average: 333.339
Monoisotopic: 333.07592138
Chemical Formula
C13H16N3NaO4S
InChI Key
DJGAAPFSPWAYTJ-UHFFFAOYSA-M
InChI
InChI=1S/C13H17N3O4S.Na/c1-10-12(14(2)9-21(18,19)20)13(17)16(15(10)3)11-7-5-4-6-8-11;/h4-8H,9H2,1-3H3,(H,18,19,20);/q;+1/p-1
IUPAC Name
sodium [(1,5-dimethyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazol-4-yl)(methyl)amino]methanesulfonate
SMILES
[Na+].CN(CS([O-])(=O)=O)C1=C(C)N(C)N(C1=O)C1=CC=CC=C1

Pharmacology

Indication

Used in the past as a powerful painkiller and fever reducer.

Pharmacodynamics

Dipyrone is a non-steroidal anti-inflammatory drug (NSAID), commonly used in the past as a powerful painkiller and fever reducer.

Mechanism of action
TargetActionsOrganism
UProstaglandin G/H synthase 1Not AvailableHuman
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity
Not Available
Affected organisms
  • Humans and other mammals
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
(4R)-limoneneThe risk or severity of adverse effects can be increased when Metamizole is combined with (4R)-limonene.Investigational
16-BromoepiandrosteroneThe risk or severity of adverse effects can be increased when Metamizole is combined with 16-Bromoepiandrosterone.Investigational
19-norandrostenedioneThe risk or severity of adverse effects can be increased when Metamizole is combined with 19-norandrostenedione.Experimental, Illicit
5-androstenedioneThe risk or severity of adverse effects can be increased when Metamizole is combined with 5-androstenedione.Experimental, Illicit
AbciximabMetamizole may increase the anticoagulant activities of Abciximab.Approved
AcebutololMetamizole may decrease the antihypertensive activities of Acebutolol.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Metamizole is combined with Aceclofenac.Approved, Investigational
AcemetacinThe risk or severity of adverse effects can be increased when Metamizole is combined with Acemetacin.Approved, Experimental, Investigational
AcenocoumarolMetamizole may increase the anticoagulant activities of Acenocoumarol.Approved, Investigational
AcetaminophenThe risk or severity of adverse effects can be increased when Metamizole is combined with Acetaminophen.Approved
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Metamizole is combined with Acetylsalicylic acid.Approved, Vet Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Metamizole.Approved
AlclofenacThe risk or severity of adverse effects can be increased when Metamizole is combined with Alclofenac.Approved, Withdrawn
AlclometasoneThe risk or severity of adverse effects can be increased when Metamizole is combined with Alclometasone.Approved
AldesleukinThe risk or severity of myelosuppression can be increased when Metamizole is combined with Aldesleukin.Approved
AldosteroneThe risk or severity of adverse effects can be increased when Metamizole is combined with Aldosterone.Experimental, Investigational
AlemtuzumabThe risk or severity of myelosuppression can be increased when Metamizole is combined with Alemtuzumab.Approved, Investigational
Alendronic acidThe risk or severity of adverse effects can be increased when Metamizole is combined with Alendronic acid.Approved
AliskirenMetamizole may decrease the antihypertensive activities of Aliskiren.Approved, Investigational
AlminoprofenThe risk or severity of adverse effects can be increased when Metamizole is combined with Alminoprofen.Experimental
AlprenololMetamizole may decrease the antihypertensive activities of Alprenolol.Approved, Withdrawn
AlprostadilThe therapeutic efficacy of Alprostadil can be decreased when used in combination with Metamizole.Approved, Investigational
AltretamineThe risk or severity of myelosuppression can be increased when Metamizole is combined with Altretamine.Approved
AmcinonideThe risk or severity of adverse effects can be increased when Metamizole is combined with Amcinonide.Approved
AmikacinMetamizole may decrease the excretion rate of Amikacin which could result in a higher serum level.Approved, Investigational, Vet Approved
AmilorideMetamizole may decrease the antihypertensive activities of Amiloride.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Metamizole is combined with Aminosalicylic Acid.Approved
AmiodaroneMetamizole may decrease the antihypertensive activities of Amiodarone.Approved, Investigational
AmsacrineThe risk or severity of myelosuppression can be increased when Metamizole is combined with Amsacrine.Approved, Investigational
AncrodMetamizole may increase the anticoagulant activities of Ancrod.Approved, Investigational
AndrographolideThe risk or severity of adverse effects can be increased when Metamizole is combined with Andrographolide.Investigational
AndrostenedioneThe risk or severity of adverse effects can be increased when Metamizole is combined with Androstenedione.Experimental, Illicit
AnecortaveThe risk or severity of adverse effects can be increased when Metamizole is combined with Anecortave.Investigational
anecortave acetateThe risk or severity of adverse effects can be increased when Metamizole is combined with anecortave acetate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Metamizole is combined with Anisodamine.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Metamizole is combined with Antipyrine.Approved, Investigational
Antithrombin III humanMetamizole may increase the anticoagulant activities of Antithrombin III human.Approved
AntrafenineThe risk or severity of adverse effects can be increased when Metamizole is combined with Antrafenine.Approved
ApixabanMetamizole may increase the anticoagulant activities of Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Metamizole is combined with Apocynin.Investigational
ApramycinMetamizole may decrease the excretion rate of Apramycin which could result in a higher serum level.Experimental, Vet Approved
ApremilastThe risk or severity of adverse effects can be increased when Metamizole is combined with Apremilast.Approved, Investigational
ArbekacinMetamizole may decrease the excretion rate of Arbekacin which could result in a higher serum level.Approved, Investigational
ArdeparinMetamizole may increase the anticoagulant activities of Ardeparin.Approved, Investigational, Withdrawn
ArgatrobanMetamizole may increase the anticoagulant activities of Argatroban.Approved, Investigational
AripiprazoleThe serum concentration of Aripiprazole can be decreased when it is combined with Metamizole.Approved, Investigational
ArotinololMetamizole may decrease the antihypertensive activities of Arotinolol.Investigational
Arsenic trioxideThe risk or severity of myelosuppression can be increased when Metamizole is combined with Arsenic trioxide.Approved, Investigational
AsenapineMetamizole may decrease the antihypertensive activities of Asenapine.Approved
AsunaprevirThe serum concentration of Asunaprevir can be decreased when it is combined with Metamizole.Approved, Investigational, Withdrawn
AtamestaneThe risk or severity of adverse effects can be increased when Metamizole is combined with Atamestane.Investigational
AtenololMetamizole may decrease the antihypertensive activities of Atenolol.Approved
AzacitidineThe risk or severity of myelosuppression can be increased when Metamizole is combined with Azacitidine.Approved, Investigational
AzapropazoneThe risk or severity of adverse effects can be increased when Metamizole is combined with Azapropazone.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Metamizole.Approved
Azficel-TThe risk or severity of adverse effects can be increased when Metamizole is combined with Azficel-T.Approved, Investigational
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Azilsartan medoxomil is combined with Metamizole.Approved, Investigational
AzosemideThe therapeutic efficacy of Azosemide can be decreased when used in combination with Metamizole.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Metamizole is combined with Balsalazide.Approved, Investigational
BecaplerminMetamizole may increase the anticoagulant activities of Becaplermin.Approved, Investigational
Beclomethasone dipropionateThe risk or severity of adverse effects can be increased when Metamizole is combined with Beclomethasone dipropionate.Approved, Investigational
BefunololMetamizole may decrease the antihypertensive activities of Befunolol.Experimental
BekanamycinMetamizole may decrease the excretion rate of Bekanamycin which could result in a higher serum level.Experimental
BelinostatThe risk or severity of myelosuppression can be increased when Metamizole is combined with Belinostat.Approved, Investigational
BenazeprilThe risk or severity of adverse effects can be increased when Metamizole is combined with Benazepril.Approved, Investigational
BendamustineThe risk or severity of myelosuppression can be increased when Metamizole is combined with Bendamustine.Approved, Investigational
BendazacThe risk or severity of adverse effects can be increased when Metamizole is combined with Bendazac.Experimental
BendroflumethiazideThe therapeutic efficacy of Bendroflumethiazide can be decreased when used in combination with Metamizole.Approved
BenorilateThe risk or severity of adverse effects can be increased when Metamizole is combined with Benorilate.Experimental
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Metamizole.Withdrawn
BenzthiazideThe therapeutic efficacy of Benzthiazide can be decreased when used in combination with Metamizole.Approved
BenzydamineThe risk or severity of adverse effects can be increased when Metamizole is combined with Benzydamine.Approved
BeraprostThe therapeutic efficacy of Beraprost can be decreased when used in combination with Metamizole.Investigational
BetamethasoneThe risk or severity of adverse effects can be increased when Metamizole is combined with Betamethasone.Approved, Vet Approved
BetaxololMetamizole may decrease the antihypertensive activities of Betaxolol.Approved, Investigational
BetrixabanThe risk or severity of bleeding can be increased when Betrixaban is combined with Metamizole.Approved, Investigational
BevacizumabThe risk or severity of myelosuppression can be increased when Metamizole is combined with Bevacizumab.Approved, Investigational
BevantololMetamizole may decrease the antihypertensive activities of Bevantolol.Approved
BevoniumThe risk or severity of adverse effects can be increased when Metamizole is combined with Bevonium.Experimental
BexaroteneThe risk or severity of myelosuppression can be increased when Metamizole is combined with Bexarotene.Approved, Investigational
BimatoprostThe therapeutic efficacy of Bimatoprost can be decreased when used in combination with Metamizole.Approved, Investigational
BisoprololMetamizole may decrease the antihypertensive activities of Bisoprolol.Approved
BivalirudinMetamizole may increase the anticoagulant activities of Bivalirudin.Approved, Investigational
BlinatumomabThe risk or severity of myelosuppression can be increased when Metamizole is combined with Blinatumomab.Approved, Investigational
BopindololMetamizole may decrease the antihypertensive activities of Bopindolol.Approved
BortezomibThe risk or severity of myelosuppression can be increased when Metamizole is combined with Bortezomib.Approved, Investigational
BosutinibThe risk or severity of myelosuppression can be increased when Metamizole is combined with Bosutinib.Approved
BromfenacThe risk or severity of adverse effects can be increased when Metamizole is combined with Bromfenac.Approved
BucillamineThe risk or severity of adverse effects can be increased when Metamizole is combined with Bucillamine.Investigational
BucindololMetamizole may decrease the antihypertensive activities of Bucindolol.Investigational
BudesonideThe risk or severity of adverse effects can be increased when Metamizole is combined with Budesonide.Approved
BufexamacThe risk or severity of adverse effects can be increased when Metamizole is combined with Bufexamac.Approved, Experimental
BufuralolMetamizole may decrease the antihypertensive activities of Bufuralol.Experimental, Investigational
BumadizoneThe risk or severity of adverse effects can be increased when Metamizole is combined with Bumadizone.Experimental
BumetanideThe therapeutic efficacy of Bumetanide can be decreased when used in combination with Metamizole.Approved
BupranololMetamizole may decrease the antihypertensive activities of Bupranolol.Approved
BusulfanThe risk or severity of myelosuppression can be increased when Metamizole is combined with Busulfan.Approved, Investigational
CabazitaxelThe risk or severity of myelosuppression can be increased when Metamizole is combined with Cabazitaxel.Approved
CandesartanThe risk or severity of adverse effects can be increased when Candesartan is combined with Metamizole.Experimental
Candesartan cilexetilThe risk or severity of adverse effects can be increased when Candesartan cilexetil is combined with Metamizole.Approved
CandoxatrilThe risk or severity of adverse effects can be increased when Metamizole is combined with Candoxatril.Experimental
CapecitabineThe risk or severity of myelosuppression can be increased when Metamizole is combined with Capecitabine.Approved, Investigational
CapsaicinThe risk or severity of adverse effects can be increased when Metamizole is combined with Capsaicin.Approved
CaptoprilThe risk or severity of adverse effects can be increased when Metamizole is combined with Captopril.Approved
CarbamazepineThe risk or severity of myelosuppression can be increased when Metamizole is combined with Carbamazepine.Approved, Investigational
Carbaspirin calciumThe risk or severity of adverse effects can be increased when Metamizole is combined with Carbaspirin calcium.Experimental, Investigational
CarboplatinThe risk or severity of myelosuppression can be increased when Metamizole is combined with Carboplatin.Approved
Carboprost TromethamineThe therapeutic efficacy of Carboprost Tromethamine can be decreased when used in combination with Metamizole.Approved
CarfilzomibThe risk or severity of myelosuppression can be increased when Metamizole is combined with Carfilzomib.Approved, Investigational
CarmustineThe risk or severity of myelosuppression can be increased when Metamizole is combined with Carmustine.Approved, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Metamizole is combined with Carprofen.Approved, Vet Approved, Withdrawn
CarteololMetamizole may decrease the antihypertensive activities of Carteolol.Approved
CarvedilolMetamizole may decrease the antihypertensive activities of Carvedilol.Approved, Investigational
CastanospermineThe risk or severity of adverse effects can be increased when Castanospermine is combined with Metamizole.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Metamizole is combined with Celecoxib.Approved, Investigational
CeliprololMetamizole may decrease the antihypertensive activities of Celiprolol.Approved, Investigational
CertoparinMetamizole may increase the anticoagulant activities of Certoparin.Approved, Investigational
ChlorambucilThe risk or severity of myelosuppression can be increased when Metamizole is combined with Chlorambucil.Approved
ChloramphenicolThe risk or severity of myelosuppression can be increased when Metamizole is combined with Chloramphenicol.Approved, Vet Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Metamizole.Approved, Investigational, Vet Approved
ChlorothiazideThe therapeutic efficacy of Chlorothiazide can be decreased when used in combination with Metamizole.Approved, Vet Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when Metamizole is combined with Chlorphenesin.Approved, Vet Approved, Withdrawn
ChlorthalidoneThe therapeutic efficacy of Chlorthalidone can be decreased when used in combination with Metamizole.Approved
CholestyramineCholestyramine can cause a decrease in the absorption of Metamizole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved, Investigational
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Metamizole is combined with Choline magnesium trisalicylate.Approved
CiclesonideThe risk or severity of adverse effects can be increased when Metamizole is combined with Ciclesonide.Approved, Investigational
CilazaprilThe risk or severity of adverse effects can be increased when Metamizole is combined with Cilazapril.Approved
CimicoxibThe risk or severity of adverse effects can be increased when Metamizole is combined with Cimicoxib.Investigational
CinoxacinMetamizole may increase the neuroexcitatory activities of Cinoxacin.Approved, Investigational, Withdrawn
CiprofloxacinMetamizole may increase the neuroexcitatory activities of Ciprofloxacin.Approved, Investigational
CisplatinThe risk or severity of myelosuppression can be increased when Metamizole is combined with Cisplatin.Approved
Citric AcidMetamizole may increase the anticoagulant activities of Citric Acid.Approved, Nutraceutical, Vet Approved
CladribineThe risk or severity of myelosuppression can be increased when Metamizole is combined with Cladribine.Approved, Investigational
ClobetasolThe risk or severity of adverse effects can be increased when Metamizole is combined with Clobetasol.Approved, Investigational
Clobetasol propionateThe risk or severity of adverse effects can be increased when Metamizole is combined with Clobetasol propionate.Approved
ClobetasoneThe risk or severity of adverse effects can be increased when Metamizole is combined with Clobetasone.Approved
ClocortoloneThe risk or severity of adverse effects can be increased when Metamizole is combined with Clocortolone.Approved
Clodronic AcidThe risk or severity of adverse effects can be increased when Metamizole is combined with Clodronic Acid.Approved, Investigational, Vet Approved
ClofarabineThe risk or severity of myelosuppression can be increased when Metamizole is combined with Clofarabine.Approved, Investigational
ClonixinThe risk or severity of adverse effects can be increased when Metamizole is combined with Clonixin.Approved
CloprostenolThe therapeutic efficacy of Cloprostenol can be decreased when used in combination with Metamizole.Vet Approved
CloranololMetamizole may decrease the antihypertensive activities of Cloranolol.Experimental
ColesevelamColesevelam can cause a decrease in the absorption of Metamizole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
ColestipolColestipol can cause a decrease in the absorption of Metamizole resulting in a reduced serum concentration and potentially a decrease in efficacy.Approved
Cortexolone 17α-propionateThe risk or severity of adverse effects can be increased when Metamizole is combined with Cortexolone 17α-propionate.Investigational
CorticosteroneThe risk or severity of adverse effects can be increased when Metamizole is combined with Corticosterone.Experimental
Cortisone acetateThe risk or severity of adverse effects can be increased when Metamizole is combined with Cortisone acetate.Approved, Investigational
CurcuminThe risk or severity of adverse effects can be increased when Metamizole is combined with Curcumin.Approved, Investigational
CyclopenthiazideThe therapeutic efficacy of Cyclopenthiazide can be decreased when used in combination with Metamizole.Experimental
CyclophosphamideThe risk or severity of myelosuppression can be increased when Metamizole is combined with Cyclophosphamide.Approved, Investigational
CyclosporineMetamizole may increase the nephrotoxic activities of Cyclosporine.Approved, Investigational, Vet Approved
CytarabineThe risk or severity of myelosuppression can be increased when Metamizole is combined with Cytarabine.Approved, Investigational
Dabigatran etexilateMetamizole may increase the anticoagulant activities of Dabigatran etexilate.Approved
DacarbazineThe risk or severity of myelosuppression can be increased when Metamizole is combined with Dacarbazine.Approved, Investigational
DactinomycinThe risk or severity of myelosuppression can be increased when Metamizole is combined with Dactinomycin.Approved, Investigational
DalteparinMetamizole may increase the anticoagulant activities of Dalteparin.Approved
DanaparoidMetamizole may increase the anticoagulant activities of Danaparoid.Approved, Withdrawn
DarexabanMetamizole may increase the anticoagulant activities of Darexaban.Investigational
DasatinibThe risk or severity of myelosuppression can be increased when Metamizole is combined with Dasatinib.Approved, Investigational
DaunorubicinThe risk or severity of myelosuppression can be increased when Metamizole is combined with Daunorubicin.Approved
DecitabineThe risk or severity of myelosuppression can be increased when Metamizole is combined with Decitabine.Approved, Investigational
DeferasiroxThe risk or severity of adverse effects can be increased when Metamizole is combined with Deferasirox.Approved, Investigational
DeflazacortThe risk or severity of adverse effects can be increased when Metamizole is combined with Deflazacort.Approved, Investigational
DelaprilThe risk or severity of adverse effects can be increased when Metamizole is combined with Delapril.Experimental
DesipramineMetamizole may decrease the antihypertensive activities of Desipramine.Approved, Investigational
DesirudinMetamizole may increase the anticoagulant activities of Desirudin.Approved
DesmopressinThe risk or severity of adverse effects can be increased when Metamizole is combined with Desmopressin.Approved
DesonideThe risk or severity of adverse effects can be increased when Metamizole is combined with Desonide.Approved, Investigational
DesoximetasoneThe risk or severity of adverse effects can be increased when Metamizole is combined with Desoximetasone.Approved
Desoxycorticosterone acetateThe risk or severity of adverse effects can be increased when Metamizole is combined with Desoxycorticosterone acetate.Approved
Desoxycorticosterone PivalateThe risk or severity of adverse effects can be increased when Metamizole is combined with Desoxycorticosterone Pivalate.Experimental, Vet Approved
DexamethasoneThe risk or severity of adverse effects can be increased when Metamizole is combined with Dexamethasone.Approved, Investigational, Vet Approved
Dexamethasone isonicotinateThe risk or severity of adverse effects can be increased when Metamizole is combined with Dexamethasone isonicotinate.Vet Approved
DexibuprofenThe risk or severity of adverse effects can be increased when Metamizole is combined with Dexibuprofen.Approved, Investigational
DexketoprofenThe risk or severity of adverse effects can be increased when Dexketoprofen is combined with Metamizole.Approved, Investigational
DexrazoxaneThe risk or severity of myelosuppression can be increased when Metamizole is combined with Dexrazoxane.Approved, Withdrawn
DextranMetamizole may increase the anticoagulant activities of Dextran.Approved, Investigational, Vet Approved
DibekacinMetamizole may decrease the excretion rate of Dibekacin which could result in a higher serum level.Experimental
Dibotermin alfaThe risk or severity of adverse effects can be increased when Metamizole is combined with Dibotermin alfa.Approved, Investigational
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Metamizole.Approved, Vet Approved
DicoumarolMetamizole may increase the anticoagulant activities of Dicoumarol.Approved
DifenpiramideThe risk or severity of adverse effects can be increased when Metamizole is combined with Difenpiramide.Experimental
DiflorasoneThe risk or severity of adverse effects can be increased when Metamizole is combined with Diflorasone.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Metamizole is combined with Diflunisal.Approved, Investigational
DifluocortoloneThe risk or severity of adverse effects can be increased when Metamizole is combined with Difluocortolone.Approved, Investigational, Withdrawn
DifluprednateThe risk or severity of adverse effects can be increased when Metamizole is combined with Difluprednate.Approved
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Metamizole.Approved
DihydrostreptomycinMetamizole may decrease the excretion rate of Dihydrostreptomycin which could result in a higher serum level.Investigational, Vet Approved
DinoprostThe therapeutic efficacy of Dinoprost can be decreased when used in combination with Metamizole.Investigational
Dinoprost TromethamineThe therapeutic efficacy of Dinoprost Tromethamine can be decreased when used in combination with Metamizole.Approved, Vet Approved
DinoprostoneThe therapeutic efficacy of Dinoprostone can be decreased when used in combination with Metamizole.Approved
DinutuximabThe risk or severity of myelosuppression can be increased when Metamizole is combined with Dinutuximab.Approved, Investigational
DocetaxelThe risk or severity of myelosuppression can be increased when Metamizole is combined with Docetaxel.Approved, Investigational
DoxorubicinThe risk or severity of myelosuppression can be increased when Metamizole is combined with Doxorubicin.Approved, Investigational
DrospirenoneMetamizole may increase the hyperkalemic activities of Drospirenone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Metamizole is combined with Droxicam.Withdrawn
DuvelisibThe risk or severity of adverse effects can be increased when Metamizole is combined with Duvelisib.Investigational
E-6201The risk or severity of adverse effects can be increased when Metamizole is combined with E-6201.Investigational
Edetic AcidMetamizole may increase the anticoagulant activities of Edetic Acid.Approved, Vet Approved
EdoxabanMetamizole may increase the anticoagulant activities of Edoxaban.Approved
EnalaprilThe risk or severity of adverse effects can be increased when Metamizole is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe risk or severity of adverse effects can be increased when Metamizole is combined with Enalaprilat.Approved
EnoxacinMetamizole may increase the neuroexcitatory activities of Enoxacin.Approved, Investigational
EnoxaparinMetamizole may increase the anticoagulant activities of Enoxaparin.Approved
EnprostilThe therapeutic efficacy of Enprostil can be decreased when used in combination with Metamizole.Experimental
EpanololMetamizole may decrease the antihypertensive activities of Epanolol.Experimental
EpirizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Epirizole.Approved
EpirubicinThe risk or severity of myelosuppression can be increased when Metamizole is combined with Epirubicin.Approved
EpitizideThe therapeutic efficacy of Epitizide can be decreased when used in combination with Metamizole.Experimental
EplerenoneMetamizole may decrease the antihypertensive activities of Eplerenone.Approved
EpoprostenolThe therapeutic efficacy of Epoprostenol can be decreased when used in combination with Metamizole.Approved
EprosartanThe risk or severity of adverse effects can be increased when Eprosartan is combined with Metamizole.Approved
EquileninThe risk or severity of adverse effects can be increased when Metamizole is combined with Equilenin.Experimental
EquilinThe risk or severity of adverse effects can be increased when Metamizole is combined with Equilin.Approved
EribulinThe risk or severity of myelosuppression can be increased when Metamizole is combined with Eribulin.Approved, Investigational
EsatenololMetamizole may decrease the antihypertensive activities of Esatenolol.Experimental
EsmololMetamizole may decrease the antihypertensive activities of Esmolol.Approved
EstroneThe risk or severity of adverse effects can be increased when Metamizole is combined with Estrone.Approved
Estrone sulfateThe risk or severity of adverse effects can be increased when Metamizole is combined with Estrone sulfate.Approved
Etacrynic acidThe therapeutic efficacy of Etacrynic acid can be decreased when used in combination with Metamizole.Approved, Investigational
EtanerceptThe risk or severity of adverse effects can be increased when Metamizole is combined with Etanercept.Approved, Investigational
EthenzamideThe risk or severity of adverse effects can be increased when Metamizole is combined with Ethenzamide.Experimental
Ethyl biscoumacetateMetamizole may increase the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
Etidronic acidThe risk or severity of adverse effects can be increased when Metamizole is combined with Etidronic acid.Approved
EtodolacThe risk or severity of adverse effects can be increased when Metamizole is combined with Etodolac.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Metamizole is combined with Etofenamate.Approved, Investigational
EtoposideThe risk or severity of myelosuppression can be increased when Metamizole is combined with Etoposide.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Metamizole is combined with Etoricoxib.Approved, Investigational
Evening primrose oilThe risk or severity of adverse effects can be increased when Metamizole is combined with Evening primrose oil.Investigational, Nutraceutical
EverolimusThe risk or severity of myelosuppression can be increased when Metamizole is combined with Everolimus.Approved
ExisulindThe risk or severity of adverse effects can be increased when Metamizole is combined with Exisulind.Investigational
FelbinacThe risk or severity of adverse effects can be increased when Metamizole is combined with Felbinac.Experimental
FenbufenThe risk or severity of adverse effects can be increased when Metamizole is combined with Fenbufen.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Metamizole is combined with Fenoprofen.Approved
FenprostaleneThe therapeutic efficacy of Fenprostalene can be decreased when used in combination with Metamizole.Vet Approved
FentiazacThe risk or severity of adverse effects can be increased when Metamizole is combined with Fentiazac.Experimental
FeprazoneThe risk or severity of adverse effects can be increased when Metamizole is combined with Feprazone.Experimental
Ferulic acidMetamizole may increase the anticoagulant activities of Ferulic acid.Experimental
FimasartanThe risk or severity of adverse effects can be increased when Fimasartan is combined with Metamizole.Approved, Investigational
Fish oilThe risk or severity of adverse effects can be increased when Metamizole is combined with Fish oil.Approved, Nutraceutical
FleroxacinMetamizole may increase the neuroexcitatory activities of Fleroxacin.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Metamizole.Approved, Withdrawn
FloxuridineThe risk or severity of myelosuppression can be increased when Metamizole is combined with Floxuridine.Approved
FluasteroneThe risk or severity of adverse effects can be increased when Metamizole is combined with Fluasterone.Investigational
FlucytosineThe risk or severity of myelosuppression can be increased when Metamizole is combined with Flucytosine.Approved, Investigational
FludarabineThe risk or severity of myelosuppression can be increased when Metamizole is combined with Fludarabine.Approved
FludrocortisoneThe risk or severity of adverse effects can be increased when Metamizole is combined with Fludrocortisone.Approved, Investigational
FluindioneMetamizole may increase the anticoagulant activities of Fluindione.Approved, Investigational
FlumequineMetamizole may increase the neuroexcitatory activities of Flumequine.Withdrawn
FlumethasoneThe risk or severity of adverse effects can be increased when Metamizole is combined with Flumethasone.Approved, Vet Approved
FlunisolideThe risk or severity of adverse effects can be increased when Metamizole is combined with Flunisolide.Approved, Investigational
FlunixinThe risk or severity of adverse effects can be increased when Metamizole is combined with Flunixin.Vet Approved
FlunoxaprofenThe risk or severity of adverse effects can be increased when Metamizole is combined with Flunoxaprofen.Experimental
Fluocinolone AcetonideThe risk or severity of adverse effects can be increased when Metamizole is combined with Fluocinolone Acetonide.Approved, Investigational, Vet Approved
FluocinonideThe risk or severity of adverse effects can be increased when Metamizole is combined with Fluocinonide.Approved, Investigational
FluocortoloneThe risk or severity of adverse effects can be increased when Metamizole is combined with Fluocortolone.Approved, Withdrawn
FluorometholoneThe risk or severity of adverse effects can be increased when Metamizole is combined with Fluorometholone.Approved, Investigational
FluorouracilThe risk or severity of myelosuppression can be increased when Metamizole is combined with Fluorouracil.Approved
FluprednideneThe risk or severity of adverse effects can be increased when Metamizole is combined with Fluprednidene.Approved, Withdrawn
FluprednisoloneThe risk or severity of adverse effects can be increased when Metamizole is combined with Fluprednisolone.Approved
FluprostenolThe therapeutic efficacy of Fluprostenol can be decreased when used in combination with Metamizole.Vet Approved
FlurandrenolideThe risk or severity of adverse effects can be increased when Metamizole is combined with Flurandrenolide.Approved
FlurbiprofenThe risk or severity of adverse effects can be increased when Metamizole is combined with Flurbiprofen.Approved, Investigational
FluticasoneThe risk or severity of adverse effects can be increased when Metamizole is combined with Fluticasone.Approved, Experimental, Investigational
Fluticasone furoateThe risk or severity of adverse effects can be increased when Metamizole is combined with Fluticasone furoate.Approved
Fluticasone propionateThe risk or severity of adverse effects can be increased when Metamizole is combined with Fluticasone propionate.Approved
Folic AcidThe therapeutic efficacy of Folic Acid can be decreased when used in combination with Metamizole.Approved, Nutraceutical, Vet Approved
FondaparinuxMetamizole may increase the anticoagulant activities of Fondaparinux.Approved, Investigational
Fondaparinux sodiumMetamizole may increase the anticoagulant activities of Fondaparinux sodium.Approved, Investigational
ForasartanThe risk or severity of adverse effects can be increased when Forasartan is combined with Metamizole.Experimental
FormestaneThe risk or severity of adverse effects can be increased when Metamizole is combined with Formestane.Approved, Investigational, Withdrawn
FosinoprilThe risk or severity of adverse effects can be increased when Metamizole is combined with Fosinopril.Approved
FramycetinMetamizole may decrease the excretion rate of Framycetin which could result in a higher serum level.Approved
FurosemideThe therapeutic efficacy of Furosemide can be decreased when used in combination with Metamizole.Approved, Vet Approved
GabexateMetamizole may increase the anticoagulant activities of Gabexate.Investigational
GarenoxacinMetamizole may increase the neuroexcitatory activities of Garenoxacin.Investigational
GatifloxacinMetamizole may increase the neuroexcitatory activities of Gatifloxacin.Approved, Investigational
GemcitabineThe risk or severity of myelosuppression can be increased when Metamizole is combined with Gemcitabine.Approved
GemeprostThe therapeutic efficacy of Gemeprost can be decreased when used in combination with Metamizole.Approved, Withdrawn
GemifloxacinMetamizole may increase the neuroexcitatory activities of Gemifloxacin.Approved, Investigational
Gemtuzumab ozogamicinThe risk or severity of myelosuppression can be increased when Metamizole is combined with Gemtuzumab ozogamicin.Approved, Investigational
GeneticinMetamizole may decrease the excretion rate of Geneticin which could result in a higher serum level.Experimental
GentamicinMetamizole may decrease the excretion rate of Gentamicin which could result in a higher serum level.Approved, Vet Approved
GENTAMICIN C1AMetamizole may decrease the excretion rate of GENTAMICIN C1A which could result in a higher serum level.Experimental
GinsengThe risk or severity of adverse effects can be increased when Metamizole is combined with Ginseng.Approved, Investigational, Nutraceutical
GrepafloxacinMetamizole may increase the neuroexcitatory activities of Grepafloxacin.Approved, Investigational, Withdrawn
GuacetisalThe risk or severity of adverse effects can be increased when Metamizole is combined with Guacetisal.Experimental
HalcinonideThe risk or severity of adverse effects can be increased when Metamizole is combined with Halcinonide.Approved, Investigational, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Metamizole is combined with Haloperidol.Approved
HE3286The risk or severity of adverse effects can be increased when Metamizole is combined with HE3286.Investigational
HeparinMetamizole may increase the anticoagulant activities of Heparin.Approved, Investigational
HigenamineThe risk or severity of adverse effects can be increased when Metamizole is combined with Higenamine.Investigational
HydralazineMetamizole may decrease the antihypertensive activities of Hydralazine.Approved
HydrochlorothiazideThe therapeutic efficacy of Hydrochlorothiazide can be decreased when used in combination with Metamizole.Approved, Vet Approved
HydrocortisoneThe risk or severity of adverse effects can be increased when Metamizole is combined with Hydrocortisone.Approved, Vet Approved
HydroflumethiazideThe therapeutic efficacy of Hydroflumethiazide can be decreased when used in combination with Metamizole.Approved, Investigational
HydroxyureaThe risk or severity of myelosuppression can be increased when Metamizole is combined with Hydroxyurea.Approved
Hygromycin BMetamizole may decrease the excretion rate of Hygromycin B which could result in a higher serum level.Vet Approved
IbandronateThe risk or severity of adverse effects can be increased when Metamizole is combined with Ibandronate.Approved, Investigational
Ibritumomab tiuxetanThe risk or severity of myelosuppression can be increased when Metamizole is combined with Ibritumomab tiuxetan.Approved, Investigational
IbrutinibThe risk or severity of myelosuppression can be increased when Metamizole is combined with Ibrutinib.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Metamizole is combined with Ibuprofen.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Metamizole is combined with Ibuproxam.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Metamizole is combined with Icatibant.Approved, Investigational
IcosapentThe risk or severity of adverse effects can be increased when Metamizole is combined with Icosapent.Approved, Nutraceutical
IdarubicinThe risk or severity of myelosuppression can be increased when Metamizole is combined with Idarubicin.Approved
IdraparinuxMetamizole may increase the anticoagulant activities of Idraparinux.Investigational
IfosfamideThe risk or severity of myelosuppression can be increased when Metamizole is combined with Ifosfamide.Approved
IloprostThe therapeutic efficacy of Iloprost can be decreased when used in combination with Metamizole.Approved, Investigational
ImatinibThe risk or severity of myelosuppression can be increased when Metamizole is combined with Imatinib.Approved
ImidaprilThe risk or severity of adverse effects can be increased when Metamizole is combined with Imidapril.Investigational
Imidazole salicylateThe risk or severity of adverse effects can be increased when Metamizole is combined with Imidazole salicylate.Experimental
IndapamideThe therapeutic efficacy of Indapamide can be decreased when used in combination with Metamizole.Approved
IndenololMetamizole may decrease the antihypertensive activities of Indenolol.Withdrawn
IndobufenThe risk or severity of adverse effects can be increased when Metamizole is combined with Indobufen.Investigational
IndomethacinThe risk or severity of adverse effects can be increased when Metamizole is combined with Indomethacin.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Metamizole is combined with Indoprofen.Withdrawn
Interferon alfa-n3The risk or severity of myelosuppression can be increased when Metamizole is combined with Interferon alfa-n3.Approved, Investigational
Interferon alfacon-1The risk or severity of myelosuppression can be increased when Metamizole is combined with Interferon alfacon-1.Approved, Investigational
IrbesartanThe risk or severity of adverse effects can be increased when Irbesartan is combined with Metamizole.Approved, Investigational
IrinotecanThe risk or severity of myelosuppression can be increased when Metamizole is combined with Irinotecan.Approved, Investigational
IsepamicinMetamizole may decrease the excretion rate of Isepamicin which could result in a higher serum level.Experimental
IsoxicamThe risk or severity of adverse effects can be increased when Metamizole is combined with Isoxicam.Withdrawn
IstaroximeThe risk or severity of adverse effects can be increased when Metamizole is combined with Istaroxime.Investigational
IxabepiloneThe risk or severity of myelosuppression can be increased when Metamizole is combined with Ixabepilone.Approved, Investigational
KanamycinMetamizole may decrease the excretion rate of Kanamycin which could result in a higher serum level.Approved, Investigational, Vet Approved
KebuzoneThe risk or severity of adverse effects can be increased when Metamizole is combined with Kebuzone.Experimental
KetoprofenThe risk or severity of adverse effects can be increased when Metamizole is combined with Ketoprofen.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Metamizole.Approved
L-PhenylalanineThe risk or severity of myelosuppression can be increased when Metamizole is combined with L-Phenylalanine.Approved, Investigational, Nutraceutical
LabetalolMetamizole may decrease the antihypertensive activities of Labetalol.Approved
LandiololMetamizole may decrease the antihypertensive activities of Landiolol.Investigational
LatanoprostThe therapeutic efficacy of Latanoprost can be decreased when used in combination with Metamizole.Approved, Investigational
Latanoprostene BunodThe therapeutic efficacy of Latanoprostene Bunod can be decreased when used in combination with Metamizole.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Metamizole.Approved, Investigational
LenalidomideThe risk or severity of myelosuppression can be increased when Metamizole is combined with Lenalidomide.Approved
LepirudinMetamizole may increase the anticoagulant activities of Lepirudin.Approved
LetaxabanMetamizole may increase the anticoagulant activities of Letaxaban.Investigational
LevobetaxololMetamizole may decrease the antihypertensive activities of Levobetaxolol.Approved, Investigational
LevobunololMetamizole may decrease the antihypertensive activities of Levobunolol.Approved
LevofloxacinMetamizole may increase the neuroexcitatory activities of Levofloxacin.Approved, Investigational
LimaprostThe therapeutic efficacy of Limaprost can be decreased when used in combination with Metamizole.Approved, Investigational
LinezolidThe risk or severity of myelosuppression can be increased when Metamizole is combined with Linezolid.Approved, Investigational
LisinoprilThe risk or severity of adverse effects can be increased when Metamizole is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Metamizole is combined with Lisofylline.Investigational
LithiumThe serum concentration of Lithium can be increased when it is combined with Metamizole.Approved
LomefloxacinMetamizole may increase the neuroexcitatory activities of Lomefloxacin.Approved, Investigational
LomustineThe risk or severity of myelosuppression can be increased when Metamizole is combined with Lomustine.Approved, Investigational
LonazolacThe risk or severity of adverse effects can be increased when Metamizole is combined with Lonazolac.Experimental
LornoxicamThe risk or severity of adverse effects can be increased when Metamizole is combined with Lornoxicam.Approved, Investigational
LosartanThe risk or severity of adverse effects can be increased when Losartan is combined with Metamizole.Approved
LoteprednolThe risk or severity of adverse effects can be increased when Metamizole is combined with Loteprednol.Approved
LoxoprofenThe risk or severity of adverse effects can be increased when Metamizole is combined with Loxoprofen.Approved, Investigational
LubiprostoneThe therapeutic efficacy of Lubiprostone can be decreased when used in combination with Metamizole.Approved, Investigational
LumiracoxibThe risk or severity of adverse effects can be increased when Metamizole is combined with Lumiracoxib.Approved, Investigational
LuprostiolThe therapeutic efficacy of Luprostiol can be decreased when used in combination with Metamizole.Vet Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Metamizole is combined with Magnesium salicylate.Approved
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Metamizole.Approved, Investigational
ME-609The risk or severity of adverse effects can be increased when Metamizole is combined with ME-609.Investigational
MechlorethamineThe risk or severity of myelosuppression can be increased when Metamizole is combined with Mechlorethamine.Approved, Investigational
Meclofenamic acidThe risk or severity of adverse effects can be increased when Metamizole is combined with Meclofenamic acid.Approved, Vet Approved
MedrysoneThe risk or severity of adverse effects can be increased when Metamizole is combined with Medrysone.Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Metamizole is combined with Mefenamic acid.Approved
MelagatranMetamizole may increase the anticoagulant activities of Melagatran.Experimental
MelengestrolThe risk or severity of adverse effects can be increased when Metamizole is combined with Melengestrol.Vet Approved
MeloxicamThe risk or severity of adverse effects can be increased when Metamizole is combined with Meloxicam.Approved, Vet Approved
MelphalanThe risk or severity of myelosuppression can be increased when Metamizole is combined with Melphalan.Approved
MepindololMetamizole may decrease the antihypertensive activities of Mepindolol.Experimental
MercaptopurineThe risk or severity of myelosuppression can be increased when Metamizole is combined with Mercaptopurine.Approved
MesalazineThe risk or severity of adverse effects can be increased when Metamizole is combined with Mesalazine.Approved
MethimazoleThe risk or severity of myelosuppression can be increased when Metamizole is combined with Methimazole.Approved
MethotrexateThe risk or severity of adverse effects can be increased when Methotrexate is combined with Metamizole.Approved
MethyclothiazideThe therapeutic efficacy of Methyclothiazide can be decreased when used in combination with Metamizole.Approved
MethylprednisoloneThe risk or severity of adverse effects can be increased when Metamizole is combined with Methylprednisolone.Approved, Vet Approved
MetipranololMetamizole may decrease the antihypertensive activities of Metipranolol.Approved
MetolazoneThe therapeutic efficacy of Metolazone can be decreased when used in combination with Metamizole.Approved
MetoprololMetamizole may decrease the antihypertensive activities of Metoprolol.Approved, Investigational
MicronomicinMetamizole may decrease the excretion rate of Micronomicin which could result in a higher serum level.Experimental
MifamurtideThe therapeutic efficacy of Mifamurtide can be decreased when used in combination with Metamizole.Approved, Experimental
MisoprostolThe therapeutic efficacy of Misoprostol can be decreased when used in combination with Metamizole.Approved
MitomycinThe risk or severity of myelosuppression can be increased when Metamizole is combined with Mitomycin.Approved
MitoxantroneThe risk or severity of myelosuppression can be increased when Metamizole is combined with Mitoxantrone.Approved, Investigational
MizoribineThe risk or severity of adverse effects can be increased when Metamizole is combined with Mizoribine.Investigational
MoexiprilThe risk or severity of adverse effects can be increased when Metamizole is combined with Moexipril.Approved
MofebutazoneThe risk or severity of adverse effects can be increased when Metamizole is combined with Mofebutazone.Experimental
MometasoneThe risk or severity of adverse effects can be increased when Metamizole is combined with Mometasone.Approved, Vet Approved
MorniflumateThe risk or severity of adverse effects can be increased when Morniflumate is combined with Metamizole.Approved
MoxifloxacinMetamizole may increase the neuroexcitatory activities of Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Metamizole.Approved, Investigational
Mycophenolic acidThe risk or severity of adverse effects can be increased when Mycophenolic acid is combined with Metamizole.Approved
NabumetoneThe risk or severity of adverse effects can be increased when Metamizole is combined with Nabumetone.Approved
NadololMetamizole may decrease the antihypertensive activities of Nadolol.Approved
NadroparinMetamizole may increase the anticoagulant activities of Nadroparin.Approved, Investigational
NafamostatMetamizole may increase the anticoagulant activities of Nafamostat.Approved, Investigational
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Metamizole.Approved
Nalidixic AcidMetamizole may increase the neuroexcitatory activities of Nalidixic Acid.Approved, Investigational
NaproxenThe risk or severity of adverse effects can be increased when Metamizole is combined with Naproxen.Approved, Vet Approved
NCX 1022The risk or severity of adverse effects can be increased when Metamizole is combined with NCX 1022.Investigational
NeamineMetamizole may decrease the excretion rate of Neamine which could result in a higher serum level.Experimental
NebivololMetamizole may decrease the antihypertensive activities of Nebivolol.Approved, Investigational
NelarabineThe risk or severity of myelosuppression can be increased when Metamizole is combined with Nelarabine.Approved, Investigational
NemonoxacinMetamizole may increase the neuroexcitatory activities of Nemonoxacin.Investigational
NeomycinMetamizole may decrease the excretion rate of Neomycin which could result in a higher serum level.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Metamizole is combined with Nepafenac.Approved, Investigational
NetilmicinMetamizole may decrease the excretion rate of Netilmicin which could result in a higher serum level.Approved, Investigational
NifenazoneThe risk or severity of adverse effects can be increased when Metamizole is combined with Nifenazone.Experimental
Niflumic AcidThe risk or severity of adverse effects can be increased when Metamizole is combined with Niflumic Acid.Approved
NilotinibThe risk or severity of myelosuppression can be increased when Metamizole is combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Metamizole is combined with Nimesulide.Approved, Investigational, Withdrawn
NitroaspirinThe risk or severity of adverse effects can be increased when Metamizole is combined with Nitroaspirin.Investigational
NorfloxacinMetamizole may increase the neuroexcitatory activities of Norfloxacin.Approved
ObinutuzumabThe risk or severity of myelosuppression can be increased when Metamizole is combined with Obinutuzumab.Approved, Investigational
OfloxacinMetamizole may increase the neuroexcitatory activities of Ofloxacin.Approved
OlaparibThe risk or severity of myelosuppression can be increased when Metamizole is combined with Olaparib.Approved
Oleoyl-estroneThe risk or severity of adverse effects can be increased when Metamizole is combined with Oleoyl-estrone.Investigational
OlmesartanThe risk or severity of adverse effects can be increased when Olmesartan is combined with Metamizole.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Metamizole.Approved
OlsalazineMetamizole may increase the nephrotoxic activities of Olsalazine.Approved
Omacetaxine mepesuccinateThe risk or severity of bleeding can be increased when Metamizole is combined with Omacetaxine mepesuccinate.Approved, Investigational
OmapatrilatThe risk or severity of adverse effects can be increased when Metamizole is combined with Omapatrilat.Investigational
OrgoteinThe risk or severity of adverse effects can be increased when Metamizole is combined with Orgotein.Vet Approved
OtamixabanMetamizole may increase the anticoagulant activities of Otamixaban.Investigational
OxaliplatinThe risk or severity of myelosuppression can be increased when Metamizole is combined with Oxaliplatin.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Metamizole is combined with Oxaprozin.Approved
Oxolinic acidMetamizole may increase the neuroexcitatory activities of Oxolinic acid.Experimental
OxprenololMetamizole may decrease the antihypertensive activities of Oxprenolol.Approved
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Metamizole.Approved, Withdrawn
PaclitaxelThe risk or severity of myelosuppression can be increased when Metamizole is combined with Paclitaxel.Approved, Vet Approved
PalbociclibThe risk or severity of myelosuppression can be increased when Metamizole is combined with Palbociclib.Approved, Investigational
PalmidrolThe risk or severity of adverse effects can be increased when Metamizole is combined with Palmidrol.Experimental, Nutraceutical
PamidronateThe risk or severity of adverse effects can be increased when Metamizole is combined with Pamidronate.Approved
ParamethasoneThe risk or severity of adverse effects can be increased when Metamizole is combined with Paramethasone.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Metamizole is combined with Parecoxib.Approved
ParomomycinMetamizole may decrease the excretion rate of Paromomycin which could result in a higher serum level.Approved, Investigational
ParthenolideThe risk or severity of adverse effects can be increased when Metamizole is combined with Parthenolide.Approved, Investigational
PazufloxacinMetamizole may increase the neuroexcitatory activities of Pazufloxacin.Investigational
PefloxacinMetamizole may increase the neuroexcitatory activities of Pefloxacin.Approved
Peginterferon alfa-2aThe risk or severity of myelosuppression can be increased when Metamizole is combined with Peginterferon alfa-2a.Approved, Investigational
Peginterferon alfa-2bThe risk or severity of myelosuppression can be increased when Metamizole is combined with Peginterferon alfa-2b.Approved
PemetrexedThe risk or severity of myelosuppression can be increased when Metamizole is combined with Pemetrexed.Approved, Investigational
PenbutololMetamizole may decrease the antihypertensive activities of Penbutolol.Approved, Investigational
Pentaerythritol TetranitrateMetamizole may increase the anticoagulant activities of Pentaerythritol Tetranitrate.Approved
Pentosan PolysulfateMetamizole may increase the anticoagulant activities of Pentosan Polysulfate.Approved
PentostatinThe risk or severity of myelosuppression can be increased when Metamizole is combined with Pentostatin.Approved, Investigational
PerindoprilThe risk or severity of adverse effects can be increased when Metamizole is combined with Perindopril.Approved
PhenindioneMetamizole may increase the anticoagulant activities of Phenindione.Approved, Investigational
PhenprocoumonMetamizole may increase the anticoagulant activities of Phenprocoumon.Approved, Investigational
PhenylbutazoneThe risk or severity of adverse effects can be increased when Metamizole is combined with Phenylbutazone.Approved, Vet Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Metamizole.Approved, Investigational
PindololMetamizole may decrease the antihypertensive activities of Pindolol.Approved, Investigational
Pipemidic acidMetamizole may increase the neuroexcitatory activities of Pipemidic acid.Experimental
PiretanideThe therapeutic efficacy of Piretanide can be decreased when used in combination with Metamizole.Approved
PirfenidoneThe risk or severity of adverse effects can be increased when Metamizole is combined with Pirfenidone.Approved, Investigational
Piromidic acidMetamizole may increase the neuroexcitatory activities of Piromidic acid.Experimental
PiroxicamThe risk or severity of adverse effects can be increased when Metamizole is combined with Piroxicam.Approved, Investigational
PirprofenThe risk or severity of adverse effects can be increased when Metamizole is combined with Pirprofen.Experimental
PitolisantThe risk or severity of adverse effects can be increased when Metamizole is combined with Pitolisant.Approved, Investigational
Platelet Activating FactorMetamizole may decrease the antihypertensive activities of Platelet Activating Factor.Experimental
PlazomicinMetamizole may decrease the excretion rate of Plazomicin which could result in a higher serum level.Investigational
PolythiazideThe therapeutic efficacy of Polythiazide can be decreased when used in combination with Metamizole.Approved
PomalidomideThe risk or severity of myelosuppression can be increased when Metamizole is combined with Pomalidomide.Approved
PonatinibThe risk or severity of myelosuppression can be increased when Metamizole is combined with Ponatinib.Approved, Investigational
Potassium CitrateMetamizole may increase the anticoagulant activities of Potassium Citrate.Approved, Investigational, Vet Approved
PractololMetamizole may decrease the antihypertensive activities of Practolol.Approved
PralatrexateThe serum concentration of Pralatrexate can be increased when it is combined with Metamizole.Approved, Investigational
PranoprofenThe risk or severity of adverse effects can be increased when Metamizole is combined with Pranoprofen.Experimental, Investigational
PrasteroneThe risk or severity of adverse effects can be increased when Metamizole is combined with Prasterone.Approved, Investigational, Nutraceutical
Prasterone sulfateThe risk or severity of adverse effects can be increased when Metamizole is combined with Prasterone sulfate.Investigational
PrednicarbateThe risk or severity of adverse effects can be increased when Metamizole is combined with Prednicarbate.Approved, Investigational
PrednisoloneThe risk or severity of adverse effects can be increased when Metamizole is combined with Prednisolone.Approved, Vet Approved
PrednisoneThe risk or severity of adverse effects can be increased when Metamizole is combined with Prednisone.Approved, Vet Approved
PregnenoloneThe risk or severity of adverse effects can be increased when Metamizole is combined with Pregnenolone.Approved, Experimental, Investigational
ProbenecidThe serum concentration of Metamizole can be increased when it is combined with Probenecid.Approved, Investigational
ProcarbazineThe risk or severity of myelosuppression can be increased when Metamizole is combined with Procarbazine.Approved, Investigational
ProglumetacinThe risk or severity of adverse effects can be increased when Metamizole is combined with Proglumetacin.Experimental
PropacetamolThe risk or severity of adverse effects can be increased when Metamizole is combined with Propacetamol.Approved, Investigational
PropafenoneMetamizole may decrease the antihypertensive activities of Propafenone.Approved
PropranololMetamizole may decrease the antihypertensive activities of Propranolol.Approved, Investigational
PropylthiouracilThe risk or severity of myelosuppression can be increased when Metamizole is combined with Propylthiouracil.Approved, Investigational
PropyphenazoneThe risk or severity of adverse effects can be increased when Metamizole is combined with Propyphenazone.Experimental
ProquazoneThe risk or severity of adverse effects can be increased when Metamizole is combined with Proquazone.Experimental
Prostaglandin B2The therapeutic efficacy of Prostaglandin B2 can be decreased when used in combination with Metamizole.Experimental
Prostaglandin G2The therapeutic efficacy of Prostaglandin G2 can be decreased when used in combination with Metamizole.Experimental
ProstaleneThe therapeutic efficacy of Prostalene can be decreased when used in combination with Metamizole.Vet Approved
Protein CMetamizole may increase the anticoagulant activities of Protein C.Approved
Protein S humanMetamizole may increase the anticoagulant activities of Protein S human.Approved
ProtocatechualdehydeMetamizole may increase the anticoagulant activities of Protocatechualdehyde.Approved
PrulifloxacinMetamizole may increase the neuroexcitatory activities of Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when Metamizole is combined with PTC299.Investigational
PuromycinMetamizole may decrease the excretion rate of Puromycin which could result in a higher serum level.Experimental
QuinaprilThe risk or severity of adverse effects can be increased when Metamizole is combined with Quinapril.Approved, Investigational
QuinethazoneThe therapeutic efficacy of Quinethazone can be decreased when used in combination with Metamizole.Approved
RaltitrexedThe risk or severity of myelosuppression can be increased when Metamizole is combined with Raltitrexed.Approved, Investigational
RamiprilThe risk or severity of adverse effects can be increased when Metamizole is combined with Ramipril.Approved
RescinnamineThe risk or severity of adverse effects can be increased when Metamizole is combined with Rescinnamine.Approved
ResveratrolThe risk or severity of adverse effects can be increased when Metamizole is combined with Resveratrol.Approved, Experimental, Investigational
ReviparinMetamizole may increase the anticoagulant activities of Reviparin.Approved, Investigational
RibostamycinMetamizole may decrease the excretion rate of Ribostamycin which could result in a higher serum level.Approved, Investigational
RilpivirineThe serum concentration of Rilpivirine can be decreased when it is combined with Metamizole.Approved
RimexoloneThe risk or severity of adverse effects can be increased when Metamizole is combined with Rimexolone.Approved
RisedronateThe risk or severity of adverse effects can be increased when Metamizole is combined with Risedronate.Approved, Investigational
RituximabThe risk or severity of myelosuppression can be increased when Metamizole is combined with Rituximab.Approved
RivaroxabanMetamizole may increase the anticoagulant activities of Rivaroxaban.Approved
RofecoxibThe risk or severity of adverse effects can be increased when Metamizole is combined with Rofecoxib.Approved, Investigational, Withdrawn
RosoxacinMetamizole may increase the neuroexcitatory activities of Rosoxacin.Approved, Investigational
RufloxacinMetamizole may increase the neuroexcitatory activities of Rufloxacin.Experimental
RuxolitinibThe risk or severity of myelosuppression can be increased when Metamizole is combined with Ruxolitinib.Approved
SacubitrilThe risk or severity of adverse effects can be increased when Sacubitril is combined with Metamizole.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Metamizole is combined with Salicylamide.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Metamizole is combined with Salicylic acid.Approved, Investigational, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Metamizole is combined with Salsalate.Approved
SaprisartanThe risk or severity of adverse effects can be increased when Saprisartan is combined with Metamizole.Experimental
SaralasinThe risk or severity of adverse effects can be increased when Saralasin is combined with Metamizole.Investigational
SarilumabSarilumab may increase the immunosuppressive activities of Metamizole.Approved, Investigational
SaxagliptinThe serum concentration of Saxagliptin can be decreased when it is combined with Metamizole.Approved
SeliciclibThe risk or severity of adverse effects can be increased when Metamizole is combined with Seliciclib.Investigational
SemapimodThe risk or severity of adverse effects can be increased when Metamizole is combined with Semapimod.Investigational
SeratrodastThe risk or severity of adverse effects can be increased when Metamizole is combined with Seratrodast.Approved
SerrapeptaseThe risk or severity of adverse effects can be increased when Metamizole is combined with Serrapeptase.Investigational
SirolimusThe risk or severity of myelosuppression can be increased when Metamizole is combined with Sirolimus.Approved, Investigational
SisomicinMetamizole may decrease the excretion rate of Sisomicin which could result in a higher serum level.Investigational
SitafloxacinMetamizole may increase the neuroexcitatory activities of Sitafloxacin.Experimental, Investigational
Sodium CitrateMetamizole may increase the anticoagulant activities of Sodium Citrate.Approved, Investigational
Sodium phosphateSodium phosphate may increase the nephrotoxic activities of Metamizole.Approved
SorafenibThe risk or severity of myelosuppression can be increased when Metamizole is combined with Sorafenib.Approved, Investigational
SotalolMetamizole may decrease the antihypertensive activities of Sotalol.Approved
SparfloxacinMetamizole may increase the neuroexcitatory activities of Sparfloxacin.Approved, Investigational
SpiraprilThe risk or severity of adverse effects can be increased when Metamizole is combined with Spirapril.Approved
SpironolactoneMetamizole may decrease the antihypertensive activities of Spironolactone.Approved
SRT501The risk or severity of adverse effects can be increased when Metamizole is combined with SRT501.Investigational
StreptomycinMetamizole may decrease the excretion rate of Streptomycin which could result in a higher serum level.Approved, Vet Approved
StreptozocinThe risk or severity of myelosuppression can be increased when Metamizole is combined with Streptozocin.Approved, Investigational
SulfasalazineThe risk or severity of adverse effects can be increased when Metamizole is combined with Sulfasalazine.Approved
SulindacThe risk or severity of adverse effects can be increased when Metamizole is combined with Sulindac.Approved, Investigational
SulodexideMetamizole may increase the anticoagulant activities of Sulodexide.Approved, Investigational
SulprostoneThe therapeutic efficacy of Sulprostone can be decreased when used in combination with Metamizole.Investigational
SuprofenThe risk or severity of adverse effects can be increased when Metamizole is combined with Suprofen.Approved, Withdrawn
SuxibuzoneThe risk or severity of adverse effects can be increased when Metamizole is combined with Suxibuzone.Experimental
TacrolimusThe risk or severity of myelosuppression can be increased when Metamizole is combined with Tacrolimus.Approved, Investigational
TafluprostThe therapeutic efficacy of Tafluprost can be decreased when used in combination with Metamizole.Approved
TalinololMetamizole may decrease the antihypertensive activities of Talinolol.Investigational
TalniflumateThe risk or severity of adverse effects can be increased when Talniflumate is combined with Metamizole.Approved
TarenflurbilThe risk or severity of adverse effects can be increased when Metamizole is combined with Tarenflurbil.Investigational
TasosartanThe risk or severity of adverse effects can be increased when Tasosartan is combined with Metamizole.Approved
Technetium Tc-99m etidronateThe risk or severity of adverse effects can be increased when Metamizole is combined with Technetium Tc-99m etidronate.Approved
Technetium Tc-99m medronateThe risk or severity of adverse effects can be increased when Metamizole is combined with Technetium Tc-99m medronate.Approved
Tedizolid PhosphateThe risk or severity of myelosuppression can be increased when Metamizole is combined with Tedizolid Phosphate.Approved
TelmisartanThe risk or severity of adverse effects can be increased when Telmisartan is combined with Metamizole.Approved, Investigational
TemafloxacinMetamizole may increase the neuroexcitatory activities of Temafloxacin.Withdrawn
TemocaprilThe risk or severity of adverse effects can be increased when Metamizole is combined with Temocapril.Experimental, Investigational
TemozolomideThe risk or severity of myelosuppression can be increased when Metamizole is combined with Temozolomide.Approved, Investigational
TemsirolimusThe risk or severity of myelosuppression can be increased when Metamizole is combined with Temsirolimus.Approved
TenidapThe risk or severity of adverse effects can be increased when Metamizole is combined with Tenidap.Experimental
TeniposideThe risk or severity of myelosuppression can be increased when Metamizole is combined with Teniposide.Approved
Tenofovir disoproxilThe risk or severity of adverse effects can be increased when Metamizole is combined with Tenofovir disoproxil.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Metamizole is combined with Tenoxicam.Approved
TepoxalinThe risk or severity of adverse effects can be increased when Metamizole is combined with Tepoxalin.Vet Approved
TerbutalineMetamizole may decrease the antihypertensive activities of Terbutaline.Approved
TeriflunomideThe risk or severity of adverse effects can be increased when Metamizole is combined with Teriflunomide.Approved
TertatololMetamizole may decrease the antihypertensive activities of Tertatolol.Experimental
ThalidomideThe risk or severity of myelosuppression can be increased when Metamizole is combined with Thalidomide.Approved, Investigational, Withdrawn
ThiotepaThe risk or severity of myelosuppression can be increased when Metamizole is combined with Thiotepa.Approved, Investigational
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Metamizole is combined with Tiaprofenic acid.Approved
Tiludronic acidThe risk or severity of adverse effects can be increased when Metamizole is combined with Tiludronic acid.Approved, Investigational, Vet Approved
TimololMetamizole may decrease the antihypertensive activities of Timolol.Approved
TinoridineThe risk or severity of adverse effects can be increased when Metamizole is combined with Tinoridine.Investigational
TioguanineThe risk or severity of myelosuppression can be increased when Metamizole is combined with Tioguanine.Approved
TixocortolThe risk or severity of adverse effects can be increased when Metamizole is combined with Tixocortol.Approved, Withdrawn
TobramycinMetamizole may decrease the excretion rate of Tobramycin which could result in a higher serum level.Approved, Investigational
TofacitinibThe risk or severity of myelosuppression can be increased when Metamizole is combined with Tofacitinib.Approved, Investigational
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Metamizole is combined with Tolfenamic Acid.Approved, Investigational
TolmetinThe risk or severity of adverse effects can be increased when Metamizole is combined with Tolmetin.Approved
TopotecanThe risk or severity of myelosuppression can be increased when Metamizole is combined with Topotecan.Approved, Investigational
TorasemideThe therapeutic efficacy of Torasemide can be decreased when used in combination with Metamizole.Approved
TositumomabThe risk or severity of myelosuppression can be increased when Metamizole is combined with Tositumomab.Approved, Investigational
TrabectedinThe risk or severity of myelosuppression can be increased when Metamizole is combined with Trabectedin.Approved, Investigational
TrandolaprilThe risk or severity of adverse effects can be increased when Metamizole is combined with Trandolapril.Approved
TranilastThe risk or severity of adverse effects can be increased when Metamizole is combined with Tranilast.Approved, Investigational
Trastuzumab emtansineThe risk or severity of myelosuppression can be increased when Metamizole is combined with Trastuzumab emtansine.Approved, Investigational
TravoprostThe therapeutic efficacy of Travoprost can be decreased when used in combination with Metamizole.Approved
TreprostinilThe risk or severity of adverse effects can be increased when Treprostinil is combined with Metamizole.Approved, Investigational
TriamcinoloneThe risk or severity of adverse effects can be increased when Metamizole is combined with Triamcinolone.Approved, Vet Approved
TriamtereneMetamizole may decrease the antihypertensive activities of Triamterene.Approved
TribenosideThe risk or severity of adverse effects can be increased when Metamizole is combined with Tribenoside.Experimental
TrichlormethiazideThe therapeutic efficacy of Trichlormethiazide can be decreased when used in combination with Metamizole.Approved, Vet Approved
TriptolideThe risk or severity of adverse effects can be increased when Metamizole is combined with Triptolide.Investigational
Trolamine salicylateThe risk or severity of adverse effects can be increased when Metamizole is combined with Trolamine salicylate.Approved
TrovafloxacinMetamizole may increase the neuroexcitatory activities of Trovafloxacin.Approved, Investigational, Withdrawn
TroxerutinMetamizole may increase the anticoagulant activities of Troxerutin.Investigational
UlobetasolThe risk or severity of adverse effects can be increased when Metamizole is combined with Ulobetasol.Approved
UnoprostoneThe therapeutic efficacy of Unoprostone can be decreased when used in combination with Metamizole.Approved, Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Metamizole is combined with Valdecoxib.Approved, Investigational, Withdrawn
ValsartanThe risk or severity of adverse effects can be increased when Valsartan is combined with Metamizole.Approved, Investigational
VancomycinThe serum concentration of Vancomycin can be increased when it is combined with Metamizole.Approved
VinblastineThe risk or severity of myelosuppression can be increased when Metamizole is combined with Vinblastine.Approved
VindesineThe risk or severity of myelosuppression can be increased when Metamizole is combined with Vindesine.Approved, Investigational
VinorelbineThe risk or severity of myelosuppression can be increased when Metamizole is combined with Vinorelbine.Approved, Investigational
VorinostatThe risk or severity of myelosuppression can be increased when Metamizole is combined with Vorinostat.Approved, Investigational
WarfarinMetamizole may increase the anticoagulant activities of Warfarin.Approved
XimelagatranMetamizole may increase the anticoagulant activities of Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Metamizole is combined with Zaltoprofen.Approved, Investigational
ZidovudineThe risk or severity of myelosuppression can be increased when Metamizole is combined with Zidovudine.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Metamizole.Approved, Investigational, Withdrawn
ZofenoprilThe risk or severity of adverse effects can be increased when Metamizole is combined with Zofenopril.Experimental
Zoledronic acidThe risk or severity of adverse effects can be increased when Metamizole is combined with Zoledronic acid.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Metamizole is combined with Zomepirac.Withdrawn
Food Interactions
Not Available

References

General References
Not Available
External Links
PubChem Compound
522325
PubChem Substance
46509035
ChemSpider
6000
ChEBI
59033
ChEMBL
CHEMBL487894
Therapeutic Targets Database
DNC000568
PharmGKB
PA166128206
Wikipedia
Dipyrone
ATC Codes
N02BB02 — Metamizole sodiumN02BB72 — Metamizole sodium, combinations with psycholepticsN02BB52 — Metamizole sodium, combinations excl. psycholeptics

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
1CompletedBasic ScienceHealthy Volunteers1
2CompletedTreatmentOther Acute Postoperative Pain1
2CompletedTreatmentPostoperative pain1
2RecruitingNot AvailableChildren / General Surgery / Pain1
3CompletedTreatmentPostoperative pain1
3SuspendedNot AvailableFevers / Sepsis1
3TerminatedTreatmentGastroenteritis1
4CompletedTreatmentFevers1
4Not Yet RecruitingTreatmentCesarean Section / Postoperative pain1
4Not Yet RecruitingTreatmentRenal Colic1
4RecruitingPreventionAnaesthesia therapy / Hip Fractures1
4RecruitingTreatmentPostoperative pain1
4TerminatedTreatmentPain1
4TerminatedTreatmentStrokes1
Not AvailableCompletedBasic SciencePlatelet Aggregation1
Not AvailableRecruitingPreventionPostoperative pain / Prophylaxis against postoperative nausea and vomiting / Vitreoretinal Surgery1
Not AvailableUnknown StatusTreatmentPain Relief1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Zhejiang Haisen Pharmaceutical Co. Ltd.
Dosage forms
Not Available
Prices
Not Available
Patents
Not Available

Properties

State
Solid
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility5.8 mg/mLALOGPS
logP1.07ALOGPS
logP-0.82ChemAxon
logS-1.8ALOGPS
pKa (Strongest Acidic)-1.2ChemAxon
pKa (Strongest Basic)-0.44ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count6ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area83.99 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity78.92 m3·mol-1ChemAxon
Polarizability31.11 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.7868
Blood Brain Barrier+0.8896
Caco-2 permeable-0.5869
P-glycoprotein substrateNon-substrate0.8148
P-glycoprotein inhibitor INon-inhibitor0.828
P-glycoprotein inhibitor IINon-inhibitor0.8107
Renal organic cation transporterNon-inhibitor0.921
CYP450 2C9 substrateNon-substrate0.8588
CYP450 2D6 substrateNon-substrate0.7959
CYP450 3A4 substrateSubstrate0.6035
CYP450 1A2 substrateNon-inhibitor0.7153
CYP450 2C9 inhibitorNon-inhibitor0.7064
CYP450 2D6 inhibitorNon-inhibitor0.8562
CYP450 2C19 inhibitorNon-inhibitor0.6768
CYP450 3A4 inhibitorNon-inhibitor0.9297
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8506
Ames testAMES toxic0.7763
CarcinogenicityCarcinogens 0.8197
BiodegradationReady biodegradable0.7192
Rat acute toxicity2.6224 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8411
hERG inhibition (predictor II)Non-inhibitor0.6724
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-0a4i-9210000000-0afef355301fc17c2ab5
GC-MS Spectrum - EI-BGC-MSsplash10-066r-9120000000-b465330a1885c099bc73

Taxonomy

Description
This compound belongs to the class of organic compounds known as phenylpyrazoles. These are compounds containing a phenylpyrazole skeleton, which consists of a pyrazole bound to a phenyl group.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Azoles
Sub Class
Pyrazoles
Direct Parent
Phenylpyrazoles
Alternative Parents
Dialkylarylamines / Pyrazolones / Benzene and substituted derivatives / Vinylogous amides / Sulfonyls / Organosulfonic acids / Heteroaromatic compounds / Alkanesulfonic acids / Lactams / Azacyclic compounds
show 5 more
Substituents
Phenylpyrazole / Dialkylarylamine / Monocyclic benzene moiety / Pyrazolinone / Benzenoid / Organic sulfonic acid or derivatives / Organosulfonic acid or derivatives / Organosulfonic acid / Sulfonyl / Alkanesulfonic acid
show 16 more
Molecular Framework
Aromatic heteromonocyclic compounds
External Descriptors
organic sodium salt (CHEBI:59033)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
General Function
Prostaglandin-endoperoxide synthase activity
Specific Function
Converts arachidonate to prostaglandin H2 (PGH2), a committed step in prostanoid synthesis. Involved in the constitutive production of prostanoids in particular in the stomach and platelets. In gas...
Gene Name
PTGS1
Uniprot ID
P23219
Uniprot Name
Prostaglandin G/H synthase 1
Molecular Weight
68685.82 Da
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Steroid hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally un...
Gene Name
CYP2B6
Uniprot ID
P20813
Uniprot Name
Cytochrome P450 2B6
Molecular Weight
56277.81 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inducer
General Function
Vitamin d3 25-hydroxylase activity
Specific Function
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation react...
Gene Name
CYP3A4
Uniprot ID
P08684
Uniprot Name
Cytochrome P450 3A4
Molecular Weight
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256]

Drug created on September 11, 2007 14:09 / Updated on June 19, 2018 06:44